Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aducanumab (BIIB037) for early Alzheimer's disease (ENVISION)
NCT05310071Phase 3Terminated
- Sponsor
- Biogen
- Start
- Jun 2022
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
A Phase 3 trial of aducanumab in Alzheimer's disease (AD), sponsored by Biogen. Started Jun 2022; status: terminated.
02
Drugs
aducanumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05310071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05310071.